Pollack A - Search Results

1

Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity.

Pollack A, Zagars GK, Rosen II. Pollack A, et al. Semin Oncol. 1999 Apr;26(2):150-61. Semin Oncol. 1999. PMID: 10597726 Review.

2

Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.

Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A. Cowen D, et al. Among authors: pollack a. Clin Cancer Res. 2002 May;8(5):1148-54. Clin Cancer Res. 2002. PMID: 12006531

3

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Pollack A, et al. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105. doi: 10.1016/s0360-3016(02)02829-8. Int J Radiat Oncol Biol Phys. 2002. PMID: 12128107 Clinical Trial.

4

Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.

Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II. Pollack A, et al. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):677-85. doi: 10.1016/s0360-3016(02)02977-2. Int J Radiat Oncol Biol Phys. 2002. PMID: 12377318 Clinical Trial.

5

Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.

Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, Kuban DA. Huang EH, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1314-21. doi: 10.1016/s0360-3016(02)03742-2. Int J Radiat Oncol Biol Phys. 2002. PMID: 12459352

6

Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study.

Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Little DJ, et al. Among authors: pollack a. Urology. 2003 Oct;62(4):707-13. doi: 10.1016/s0090-4295(03)00504-1. Urology. 2003. PMID: 14550448 Clinical Trial.

7

Hazards of dose escalation in prostate cancer radiotherapy.

Kuban D, Pollack A, Huang E, Levy L, Dong L, Starkschall G, Rosen I. Kuban D, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1260-8. doi: 10.1016/s0360-3016(03)00772-7. Int J Radiat Oncol Biol Phys. 2003. PMID: 14630260 Clinical Trial.

8

Intrafraction prostate motion during IMRT for prostate cancer.

Huang E, Dong L, Chandra A, Kuban DA, Rosen II, Evans A, Pollack A. Huang E, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):261-8. doi: 10.1016/s0360-3016(02)02738-4. Int J Radiat Oncol Biol Phys. 2002. PMID: 12023128

9

Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.

Zagars GK, Pollack A, von Eschenbach AC. Zagars GK, et al. Among authors: pollack a. Cancer. 1997 Apr 1;79(7):1370-80. Cancer. 1997. PMID: 9083160

10

Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.

Lankford SP, Pollack A, Zagars GK. Lankford SP, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):327-33. doi: 10.1016/s0360-3016(96)00627-x. Int J Radiat Oncol Biol Phys. 1997. PMID: 9226319

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

947 results

Search Page